FLT1 and preeclampsia: These effects appeared to be attributable to increased secretion of the soluble receptor, soluble vascular endothelial growth factor receptor-1 (sVEGFR-1, also known as sFLT1), by preeclampsia explants, consistent with the elevated placental secretion of sFLT1 in vivo[5].